Page last updated: 2024-09-05

sorafenib and veliparib

sorafenib has been researched along with veliparib in 2 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(veliparib)
Trials
(veliparib)
Recent Studies (post-2010) (veliparib)
6,5207305,25132587286

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)veliparib (IC50)
Poly [ADP-ribose] polymerase 1Homo sapiens (human)0.0469
Protein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)1.9027
Poly [ADP-ribose] polymerase 2Homo sapiens (human)0.0688
Protein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)3.4837
Protein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)2.089

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H1

Trials

1 trial(s) available for sorafenib and veliparib

ArticleYear
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure

2015

Other Studies

1 other study(ies) available for sorafenib and veliparib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013